Mizuho cuts price targets on LifeMD and Cerebras, keeps Outperform
Mizuho kept Outperform ratings on LifeMD and Cerebras Systems but lowered price targets, per TradingView. LifeMD target falls to $6, Cerebras to $240.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Mizuho kept its Outperform rating on LifeMD and cut its price target to $6 from $7, a reduction of 14.3%. The new target points to roughly 262.5% upside from the November 12 close of $1.66. TradingView, which cites Benzinga for its price and rating data, reported the change.
The same bank kept Cerebras Systems at Outperform while trimming its target to $240 from $300, a 20% reduction. That target suggests about 145.5% potential gain from the November 12 close of $97.75. Over the past 30 days, the five latest analyst notes on Cerebras set targets between $155 and $200.
why it matters
A target revision from a single brokerage rarely moves the broader market. For investors in these stocks, the reasons behind the cut matter more than the targets themselves, which are analyst opinions rather than forecasts of where prices will go.
tags
instruments
sources
- Mizuho maintains LifeMD at Outperform, lowers price target to $6 from $7 — TradingView, 13 November 2026 at 17:04 UTC
- Mizuho maintains Cerebras Systems at Outperform, lowers price target to $240 from $300 — TradingView, 13 November 2026 at 17:03 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗